Postoperative infection of endoscopic submucosal dissection of early colorectal neoplasms: a case controlled-study using a Japanese database

Takahiro Muro* PhD, Norihide Higuchi* PhD, Masanobu Imamura* PhD, Hiroo Nakagawa* PhD, Masayuki Honda† PhD, Kazuhiko Nakao‡ MD PhD, Koichi Izumikawa §, MD PhD, Hitoshi Sasaki* PhD, Takashi Kitahara* PhD

*Department of Clinical Pharmacy, Nagasaki University Hospital, †Department of Medical Information, Nagasaki University Hospital, ‡Department of Gastroenterology and Hepatology, Nagasaki University Hospital, *§* Infection Control and Education Center, Nagasaki University Hospital.

Address correspondence to: Takahiro Muro

Department of Clinical Pharmacy, Nagasaki University Hospital

1-7-1 Sakamoto, Nagasaki, Nagasaki, 852-8501, Japan

E-mail: muroth1@nagasaki-u.ac.jp

TEL +81-95-819-7249 FAX +81-95-819-7251

Keywords: Antibiotic Prophylaxis, Surgical Wound Infection, Pharmacoepidemiology

SUMMARY

What is known and objective: Endoscopic submucosal dissection of early colorectal neoplasms (ESD - ECN) is known to be an operation with risk of contamination, possibly requiring preoperative antimicrobial prophylaxis for prevention of postoperative infection. However, an evaluation of the need for preoperative antimicrobial prophylaxis of ESD – ECN has yet to be reported. The objective of this study was to determine whether preoperative antimicrobial prophylaxis is associated with a reduced incidence of postoperative infection following ESD - ECN.

Methods: The present retrospective case-controlled study utilized a database built from the medical records of 14 university hospitals throughout Japan. Patients who were admitted and discharged from the hospital from April 2012 to October 2013 and who had undergone ESD - ECN were included in the study. Patients who had been undergone any other operation during their course of hospitalization, and patients who were prescribed antimicrobial agents for reasons other than postoperative infection or for prophylaxis were excluded. Characteristics of the study population, preoperative antimicrobial prophylaxis, and antimicrobial therapy for postoperative infection were investigated. In addition, we compared the characteristics of patients with postoperative infection (PI) and those with no postoperative infection (NPI). Univariate analyses were used to estimate the odds ratios (OR) and 95% confidence intervals (95%CI).

Results and discussion: We obtained the records of 522 patients who had undergone ESD - ECN from the database. After application of exclusion criteria, 421 patients were enrolled. The postoperative infection rate was 1.2%. Peritonitis was found most to be the most common postoperative infection (44%). Preoperative antimicrobial prophylaxis was used for 314 patients (75%), with a median duration of 3.0 (range 1 - 11) days. Cefotiam was most frequently prescribed for preoperative antimicrobial prophylaxis (56%). Antimicrobial therapies were started 1 to 10 days after ESD - ECN for a duration of 1 to 14 days. Preoperative antimicrobial prophylaxis was not associated with postoperative infection rate, with an OR (95%CI) of 0.73 (0.08 – 6.61). However, digestive tract perforation was shown to be associated with postoperative infection, and had an OR (95%CI) of 17.1 (1.66-176.45).

What is new and conclusion: Postoperative infection is an exceedingly rare event following ESD - ECN. Preoperative antimicrobial prophylaxis had no significant effect on postoperative infection following ESD - ECN, and thus may be unnecessary. Instead, prevention of digestive tract perforation may be more critical for the decrease in postoperative infections.

What is known and objective

Endoscopic submucosal dissection (ESD) is a variant of endoscopic mucosal resection (EMR), and is a technique for resection of early gastrointestinal tract cancers. ESD is used primarily in the stomach, but is also increasingly being applied in the colon and rectum^{1, 2)}. The technique involves identifying the margins of the polyp, submucosal injection, and circumferential dissection of the tumor-bearing mucosa and submucosa using various diathermic knives. The aim of ESD is to achieve an en-bloc resection of a sessile lesion, irrespective of its size. This facilitates histological evaluation and improves the rate of curative resection, even for carcinomas with early submucosal invasion³⁾.

Postoperative infections are a major contributor to healthcare-associated infections. Gastrointestinal procedures are thought to have the highest risk for postoperative infection due to exposure to intraluminal bacteria⁴⁾. Therefore, preoperative antimicrobial prophylaxis is warranted for patients undergoing gastrointestinal surgery involving the colon or rectum. ESD of early colorectal neoplasms (ESD - ECN) is considered to be an operation with risk of contamination, possibly requiring preoperative antimicrobial prophylaxis for the prevention of postoperative infection. Because the ESD procedure requires advanced skill and extensive training to achieve a satisfactory level of ability, the use of this technique has been somewhat limited. Therefore, the evaluation of the need for preoperative antimicrobial prophylaxis for ESD has not been sufficient. The objective of this study was to determine if preoperative antimicrobial prophylaxis is associated with a reduced incidence of postoperative infection following ESD - ECN.

Methods

Study Design and Data Source

This study was a retrospective case-controlled study utilizing the Platform for Clinical Information Statistical Analysis (CISA) database, which is composed of clinical data from 14 university hospitals throughout Japan. The CISA database contains data on approximately 2.45 million unique patients, a cumulative total of 1.25 million inpatients, a cumulative total of 37.79 million outpatients, 32.86 million prescriptions for inpatients, and 14.50 million prescriptions for outpatients. These data were collected from the medical records from each facility after removing personal information and irreversibly anonymizing the data. At present, data on medical treatment results, such as test results and interviews, information on palpation, and images are not included in the database. Diagnostic codes were established according to both the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) and the Japanese Receipt Disease Name Master (JRDNM). Drug codes were established

according to the Anatomical Therapeutic Chemical Classification System (ATC) code. In the present study, only data obtained from April 2012 to October 2013 were analyzed.

Population and Definitions

Data on patients who were admitted and discharged from the hospital from April 2012 to October 2013 and who had undergone ESD - ECN were collected from the CISA database. To reduce any possible influence of the patients' preoperative conditions, patients who had undergone ESD - ECN more than 4 days after the date of admission were excluded. Four days was selected because this duration was the most generally period from hospitalization to do ESD – ECN in Japan. Patients who had undergone any other operation other than their first ESD - ECN procedure during their course of hospitalization, such as those who had undergone additional tumorectomy or ESD for the same or different region, were also excluded. Patients who were prescribed antimicrobial agents for treatment of conditions other than postoperative infection were excluded, as were patients who were prescribed antimicrobial agents for purposes other than postoperative infection or prophylaxis. The patients remaining after application of the exclusion criteria was divided into two groups, those who had been postoperative infection (PI) and those who had been not PI (NPI) (Fig. 1).

Codes from the Japanese Receipt Disease Name Master were used for definition of postoperative infection. Codes for infectious diseases were selected by excluding infections originating from regions other than the abdomen, such as pneumonia, from all disease codes of the study population, and defined the remaining as Postoperative Infection Codes (PIC). In the present study, antimicrobial therapy for postoperative infection was defined as antimicrobial therapy administered to patients who were assigned a PIC after undergoing ESD - ECN. Thus, the postoperative infection group (PI) was defined as patients who were treated with antimicrobial therapy for postoperative infection.

Preoperative antimicrobial prophylaxis was defined as antibiotic administration during the first day of hospitalization to the day of ESD - ECN.

Epidemiological Research and Statistical Methods

Characteristics of the study population, use of preoperative antimicrobial prophylaxis, and administration of antimicrobial therapy for postoperative infection were collected from the database for epidemiological evaluation. JRDNM were used for definition of the perforation of the digestive tract. Perforation of the digestive tract was defined as patients who were assigned JRDNM codes that were meaning "perforation of the digestive tract" in the disease name after undergoing ESD – ECN and counted. Additionally, the duration of hospitalization after ESD – ECN, and the number of patients with malignant tumorrelated diseases were collected for comparison between the PI and NPI groups. We compared the PI and NPI groups using the Wilcoxon rank sum test for continuous variables, the chi-square, or Fisher's exact test for dichotomous variables. Differences were considered significant when P < 0.05. Univariate analyses was used to determine independent predictors of postoperative infection and to obtain odds ratios (OR), and the 95% confidence interval (95%CI) for each OR was calculated. Statistical significance was determined by 95% confidence intervals, not including 1.00 for logistic analyses. We introduced preoperative antimicrobial prophylaxis and digestive tract perforations as groups of variables into the model, because these are well known to be associated with postoperative infection.

Ethics statement

Because the data utilized in this study were provided to us already anonymized by the database provider, CISA, the study was exempted from obtaining informed consent from individual patients according to the local ethical guidelines for epidemiological research. This study and the waiver of informed consent were approved by the Nagasaki University Hospital ethics committee (14102796).

Results and discussion

1. Characteristics of the study population:

We obtained data on 522 patients who had undergone ESD - ECN from the CISA database. After applying the exclusion criteria, 421 patients were enrolled in the present study (Figure 1). The postoperative infection rate was 1.2%. Types of neoplasms observed in the study population are shown in Table 1. The majority of the patients had malignant neoplasms of the colon (45%) or rectum (14%). Perforation of the digestive tract was observed in 2% of patients. The characteristics of postoperative infection of the study population are shown in Table 2. Peritonitis (including generalized, circumscribed, and perforative peritonitis) were the most common postoperative infection (44%). Only two cases were reported to have developed sepsis (0.5%).

2. Characteristics of preoperative antimicrobial prophylaxis:

Preoperative antimicrobial prophylaxis was used for 314 patients (75%). The median dosing period of preoperative antimicrobial prophylaxis was 3.0 (range 1 - 11) days. Table 3 shows the duration of the preoperative antimicrobial prophylaxis per generic name. Cefotiam was the most commonly prescribed preoperative antimicrobial prophylaxis (56%), with a median dosing period of 3.0 days. Cefmetazole were the

second most frequently prescribed prophylaxis (17%), with a median dosing period of 2.5 days.

3. Antimicrobial therapy for postoperative infection:

The median duration of antimicrobial therapy for postoperative infection was 4 days; the characteristics are shown in Table 4. Six agents, including combination therapy, were used for treatment of postoperative infection, and were started 1 to 10 days after ESD - ECN for a duration of 1 to 14 days.

4. Comparison of the PI and NPI groups:

Characteristics of the PI and NPI groups are shown in Table 5, with no significant differences between the two groups. Table 6 shows the duration of the preoperative antimicrobial prophylaxis per generic name of PI. Cefotiam was the most commonly prescribed preoperative antimicrobial prophylaxis (50%) of PI, too. Univariate analyses of PI and NPI is shown in Table 7. Preoperative antimicrobial prophylaxis was not associated with postoperative infection, and had an OR (95%CI) of 0.73 (0.08 – 6.61). However, perforation of the digestive tract was associated with postoperative infection, and had an OR (95%CI) of 17.1 (1.66-176.45).

The present results suggested that there is no significant correlation between preoperative antimicrobial prophylaxis and incidence of postoperative infection after ESD - ECN.

Instead, perforation of the digestive tract was found to increase postoperative infection approximately 17-fold. In present study, it is not possible to perform multivariate logistic regression analysis, because the low number of patients with postoperative infection. So we conducted univariate analyses. Therefore, our results may include the confounding factors.

The postoperative infection rate in the present study was 1.2%, and was lower than that rate previously reported for whole colon surgery $(15\%)^{5}$. Sepsis had developed in only 2 patients (0.5%). Similarly, Minn et al. reported a low bacteremia rate (2.5%) associated with ESD or endoscopic mucosal resection (EMR)⁶, suggesting that this was due to the low possibility of direct injection into a blood vessel during submucosal injection⁶⁾. This may also be the case in ESD, which is usually used for resecting a large lesion, and consequently results in a considerable amount of exposed submucosa, requiring a large number of submucosal injections. Therefore, ESD may have a higher risk for postoperative infection than EMR. However, ESD has considerably fewer opportunities of injury to blood vessels compared with general colon surgery. Unlike an open abdominal surgery, ESD does not remove the digestive tract, and does not spill bacteria-laden intestinal contents into the abdomen. Supporting this, the present study found that perforation of the digestive tract was an important contributor to postoperative infection.

The reduced incidence in spilling bacteria-laden intestinal contents into the abdomen may contribute to the lower postoperative infection rate of ESD. The use of second-generation cephalosporin (cefoxitin or cefotetan) or cefazolin plus metronidazole is recommended as intravenous antimicrobial prophylaxis for colorectal surgery^{4, 7)}. In the present study, 76% of preoperative antimicrobial prophylaxes were second-generation cephalosporin, and the selection of antibiotics used in the study population was shown to be reasonable. On the other hand, the median duration of antimicrobial prophylaxis was 3.0 (range 1 -11) days, which was longer than the reported 24-hour duration used in common practice⁸). Nelson et al. reported that there was no need for a second intraoperative dose, or any postoperative doses, when the antibiotic was used for the purpose of prophylaxis of ESD or EMR⁶. However, Japanese guidelines on the management of infectious diseases has reported that antimicrobial prophylaxis for a duration of 2 days was acceptable, but over 3 days increased the risk of infection with antimicrobial resistant bacteria⁹⁾. Therefore, these results suggested overall adherence to the Japanese guidelines for antimicrobial prophylaxis duration. Nearly all antimicrobial agents used for postoperative infection were those selective for anaerobic bacteria. Whether these choices in antibiotics were optimal cannot be determined with confidence due to the lack of cultivation test results in the database, and is one of the limitations of the present study. Furthermore, the present study was unable to assess treatment result data, such as interviews and palpation information, nor were images available for investigation. Therefore, postoperative infection was defined in a two-step process, first identifying those patients diagnosed with an infectious disease obtained from the case records and then identifying those who were prescribed an antibiotic.

What is new and conclusion

Postoperative infection is an exceedingly rare event following ESD - ECN. Preoperative antimicrobial prophylaxis had no significant effect on postoperative infection following ESD - ECN, and thus may be unnecessary. On the other hand, the prevention of digestive tract perforation is important for decreasing the incidence of postoperative infection.

References

 Toyonaga T, Man-I M, Morita Y, Sanuki T, Yoshida M, Kutsumi H, Inokuchi H, Azuma T. The new resources of treatment for early stage colorectal tumors: EMR with small incision and simplified endoscopic submucosal dissection. *Digestive Endoscopy*.
2009; **21** Suppl 1, S31-7. doi: 10.1111/j.1443-1661.2009.00872.x. (2) Sakamoto N, Osada T, Shibuya T, Beppu K, Matsumoto K, Mori H, Kawabe M, Nagahara A, Otaka M, Ogihara T, Watanabe S. Endoscopic submucosal dissection of large colorectal tumors by using a novel spring-action S-O clip for traction (with video). *Gastrointestinal Endoscopy.* 2009; **69**, 1370-1374. doi: 10.1016/j.gie.2008.12.245. Epub 2009 Apr 28.

(3) Seitz U, Bohnacker S, Soehendra N. Endoscopic removal of large colon polyps. In: UpToDate, Saltzman JR (Ed), UpToDate Waltham, MA. (Accessed on November 25, 2014.)

(4) Anderson DJ, Sexton DJ. Control measures to prevent surgical site infection following gastrointestinal procedures in adults. In: UpToDate, Harris A (Ed), UpToDate Waltham, MA. (Accessed on November 25, 2014.)

(5) Baum ML, Anish DS, Chalmers TC, Sacks HS, Smith H Jr, Fagerstrom RM. A survey of clinical trials of antibiotic prophylaxis in colon surgery: evidence against further use of no-treatment controls. *The New England journal of medicine*. 1981, **305**, 795-799.

(6) Min BH, Chang DK, Kim DU, Kim YH, Rhee PL, Kim JJ, Rhee JC. Low frequency of bacteremia after an endoscopic resection for large colorectal tumors in spite of extensive submucosal exposure. *Gastrointestinal Endoscopy*. 2008, **68**, 105-110. doi: 10.1016/j.gie.2007.11.051. Epub 2008 Apr 9.

(7) Nelson RL, Gladman E, Barbateskovic M. Antimicrobial prophylaxis for colorectal surgery. *The Cochrane database of systematic reviews*. 2014 May 9; 5: CD001181. doi:

10.1002/14651858. CD001181.pub4, (Accessed on October 7, 2014).

(8) Bratzler DW, Houck PM; Surgical Infection Prevention Guideline Writers Workgroup. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. *American journal of surgery*. 2005 **189**, 395-404.

(9) Mikamo H, Takesue Y, Nakamura H, Fukushima R, Mizusawa M. "Prevention of postoperative infection". The JAID / JSC Guide to Clinical Management of Infectious Diseases. Guide to Clinical Management of Infectious Diseases committee of The Japanese Association for Infectious Diseases and Japanese Society of Chemotherapy ed. The Japanese Association for Infectious Diseases and Japanese Society of Chemotherapy, and Japanese Society of Chemotherapy 2011, p.182-188.




Figure 1 Flow chart for selection of study population

Table 1 Patient neoplasms

| ICD10 c | ode Description | r | n (%) |) | _ |
|---------|--|-----|-------|-----|---|
| C18 | Malignant neoplasm of colon | 347 | (4 | 45) | _ |
| C20 | Malignant neoplasm of rectum | 109 | (| 14) | |
| C78 | Secondary malignant neoplasm of respiratory and digestive organs | 52 | (| 7) | |
| C16 | Malignant neoplasm of stomach | 47 | (| 6) | |
| C34 | Malignant neoplasm of bronchus and lung | 32 | (| 4) | |
| C25 | Malignant neoplasm of pancreas | 24 | (| 3) | |
| C79 | Secondary malignant neoplasm of other and unspecified sites | 19 | (| 2) | |
| C22 | Malignant neoplasm of liver and intrahepatic bile ducts | 18 | (| 2) | |
| C61 | Malignant neoplasm of prostate | 14 | (| 2) | |
| C67 | Malignant neoplasm of bladder | 11 | (| 1) | |
| C80 | Malignant neoplasm, without specification of site | 10 | (| 1) | |
| C15 | Malignant neoplasm of oesophagus | 9 | (| 1) | |
| C50 | Malignant neoplasm of breast | 8 | (| 1) | |
| C91 | Lymphoid leukaemia | 8 | (| 1) | |
| C77 | Secondary and unspecified malignant neoplasm of lymph nodes | 7 | (| 1) | |
| C85 | Other and unspecified types of non-Hodgkin lymphoma | 6 | (| 1) | |
| C19 | Malignant neoplasm of rectosigmoid junction | 4 | (| 1) | |
| | Others | 41 | (| 5) | |

ICD10: International Statistical Classification of Diseases and Related Health Problems 10th revision Including multiple primaries and metastases

| PIC number* | Postoperative infection [†] | n |
|-------------|--------------------------------------|---|
| 389004 | sepsis | 2 |
| 8833267 | diarrheal disease | 2 |
| 91023 | enteritis | 1 |
| 5679005 | generalized peritonitis | 1 |
| 5679007 | circumscribed peritonitis | 1 |
| 5679012 | perforative peritonitis | 1 |
| 5679015 | peritonitis | 1 |

*: Japanese Receipt Disease Name Master was used for the definition of postoperative infection.

†: Codes for infectious diseases were selected by excluding infections originating from regions other than the abdomen, such as pneumonia, from all disease codes of the study population, and defined the remaining as Postoperative Infection Codes (PIC).

Includes complex infections.

| ATC level5 name | n* | (| % |) | | ration (d), lian (range) |
|---|--------------|-------------|-------------|-------------|--------------------------|-------------------------------|
| Cefotiam | 182 | (| 56 |) | 3.0 | (1-7) |
| Cefmetazole | 56 | (| 17 |) | 2.5 | (1-11) |
| Ampicillin and enzyme inhibitor | 46 | (| 14 |) | 3.0 | (1-7) |
| Meropenem | 10 | (| 3 |) | 5.0 | (4-6) |
| Cefazolin | 10 | (| 3 |) | 3.0 | (1-3) |
| Flomoxef | 8 | (| 2 |) | 2.0 | (2-4) |
| Ceftriaxone | 7 | (| 2 |) | 3.0 | (1-9) |
| Cefoperazone, combination | 5 | (| 2 |) | 3.0 | (2-9) |
| Clindamycin | 1 | (| 0 |) | 4.0 | (-) |
| Cefazolin Flomoxef Ceftriaxone Cefoperazone, combination | 10 8 7 | (((| 3 2 2 |))) | 3.0 2.0 3.0 3.0 | (1-3) (2-4) (1-9) |

Table 3 Preoperative antimicrobial prophylaxis

*: including combination therapy ATC: Anatomical Therapeutic Chemical Classification System

Table 4 Antimicrobial therapy for postoperative infection

| ATC level5 name | n* | Start of administration (days after ESD) | Duration (d) |
|-----------------------------------|----|--|-----------------|
| Sulfamethoxazole and trimethoprim | 1 | 7 | 2 |
| Metronidazole | 1 | 4 | 14 |
| Doripenem | 1 | 5 | 4 |
| Cefazolin | 1 | 2 | 1 |
| Piperacillin and enzyme inhibitor | 1 | 10 | 5 |
| Cefmetazole | 1 | 1 | 4 |

*: including combination therapy ATC: Anatomical Therapeutic Chemical Classification System

| | PI | NPI | P value |
|---|--------------|--------------|---------|
| N | 5 | 416 | - |
| Age (y), median (range) | 73 (54 - 87) | 68 (54 - 92) | 0.72 |
| Duration of stay after ESD (d), median (range) | 8 (5 - 22) | 6 (3 - 20) | 0.03 |
| Male n (%) | 3 (60) | 245 (59) | 1.00 |
| Classification of Diseases* | | | |
| Infectious and parasitic diseases | 5 | 119 | 0.91 |
| Neoplasms | 5 | 414 | |
| Diseases of the blood and blood-forming organs and disorders | 4 | 100 | |
| involving the immune system | 4 | 108 | |
| Endocrine, nutritional, and metabolic diseases | 5 | 196 | |
| Mental and behavioral disorders | 1 | 55 | |
| Diseases of the nervous system | 3 | 81 | |
| Diseases of the eye and adnexa | 2 | 41 | |
| Diseases of the ear and mastoid process | | 17 | |
| Diseases of the circulatory system | 4 | 177 | |
| Diseases of the respiratory system | 4 | 103 | |
| Diseases of the digestive system | 5 | 295 | |
| Diseases of the skin and subcutaneous tissue | 3 | 65 | |
| Diseases of the musculoskeletal system and connective tissue | 3 | 99 | |
| Diseases of the genitourinary system | 3 | 74 | |
| Pregnancy, childbirth, and the puerperium | | 11 | |
| Congenital malformations, deformations, and chromosomal abnorr | na 1 | 7 | |
| Symptoms, signs, and abnormal clinical and laboratory findings, ne elsewhere classified | | 144 | |
| Injury, poisoning, and other consequences of external causes | 3 | 32 | |
| Factors influencing health status and contact with health services | | 18 | |
| Number of malignant tumor-related diseases n (%) | | | 0.15 |
| | + | 9 (2) | |
| | 1 | 143 (32) | |
| | 2 3 (60) | 135 (11) | |
| | 3 1 (20) | 44 (7) | |
| | 4 | 29 (4) | |
| | 5 | 16 (4) | |
| | 5 1 (20) | 40 (10) | |
| Preoperative antimicrobial prophylaxis n (%) | 4 (80) | 310 (75) | 0.81 |
| Duration of preoperative antimicrobial prophylaxis (d), median | 5 (2 - 9) | 3 (1 - 11) | 0.07 |

Table 5 Characteristics of the PI and NPI groups

PI: postoperative infection group; NPI: no postoperative infection group;

*; International Statistical Classification of Diseases and Related Health Problems 10th revision (ICD-10) code, including overlap

†; Patients whose abnormal tissue samples were found to be not cancerous after postoperative pathological examination

We compared the baseline characteristics of the PI and NPI groups using the Wilcoxon rank sum test for continuous variables, the Yates' chi-square, or Fisher's exact test for discrete variables.

| ATC level5 name | n | (%) Duration (d), median (range) |
|---------------------------|---|-------------------------------------|
| Cefotiam | 2 | (50) 5.0 (5-5) |
| Cefmetazole | 1 | (25) 2.0 (-) |
| Cefoperazone, combination | 1 | (25) 9.0 (-) |

Table 6 Preoperative antimicrobial prophylaxis of PI

Table 7Univariate analyses of PI versus NPI

| | PI | NPI | OR | 95% CI |
|--|-----------|----------|------|-------------|
| Preoperative antimicrobial prophylaxis n, (% | 6) 4 (80) | 310 (75) | 0.73 | 0.08-6.61 |
| Perforation of the digestive tract n, (%) | 1 (20) | 6(1) | 17.1 | 1.66-176.45 |

PI: postoperative infection group; NPI: no postoperative infection group; OR: Odds ratios; 95% CI: 95% confidence interval